Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co‐infection in northwest Ethiopia

Abstract

To describe the clinical presentation of patients with visceral leishmaniasis (VL) with and without human immunodeficiency virus (HIV) co-infection and factors associated with poor outcome in northwest Ethiopia. Retrospective review of 241 patients with VL (92 with and 149 without HIV co-infection). HIV co-infection was present in 92 (38%) of the patients. Clinical presentation of VL was indistinguishable between patients with and without HIV co-infection. Co-infected patients had a poorer outcome i.e. either death or treatment failure (31.5%vs. 5.6%, P < 0.001). The presence of tuberculosis or sepsis syndrome among patients with VL and HIV co-infected independently predicted death or treatment failure [odds ratio 4.5 (95% CI 1.47-13.92, P = 0.009) and 9.1 (95% CI 2.16-37.97, P = 0.003), respectively]. Despite having similar clinical presentation at the time of diagnosis, VL and HIV co-infected patients had a higher mortality and treatment failure than immunocompetent patients. The frequency of HIV co-infection among patients with VL is high in the study area, and this co-infection was associated with death or treatment failure. The clinical management of VL in HIV co-infected patients is a major challenge that requires new treatment approaches to improve its outcome.